1-20 of 153 Search Results for

incretin

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book Chapter
Series: Frontiers in Diabetes
Volume: 19
Published: 12 August 2008
10.1159/000152022
EISBN: 978-3-8055-8641-2
... Abstract The current treatment options for type 2 diabetes do not achieve the glycemic goals. Improving islet function by incretin hormone action is a novel and attractive therapeutic approach. There are two different approaches to utilize incretin action in the treatment of type 2 diabetes...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475731
EISBN: 978-3-318-05974-8
... Abstract Enteroendocrine cells (EEC) have been studied extensively for their ability to regulate gastrointestinal motility and insulin release by secretion of peptide hormones. In particular, the L cell-derived incretin glucagon-like peptide 1 has gained enormous attention due to its...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
10.1159/000360598
EISBN: 978-3-318-02674-0
... Abstract As cardiovascular (CV) disease remains the major cause of mortality and morbidity in type 2 diabetes mellitus, reducing macrovascular complications has been a major target of antiglycemic therapies. Emerging evidence suggests that incretin-based therapies are safe and may provide CV...
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
10.1159/000334509
EISBN: 978-3-8055-9944-3
... Abstract Incretin hormones play a key role in the regulation of postprandial insulin release. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) account for approximately 90% of the incretin effect, but only GLP-1 has been shown to play a role in the control...
Book Chapter
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475730
EISBN: 978-3-318-05974-8
... Abstract Incretins are hormones secreted into the blood stream from the gut mucosa in response to nutrient intake. They have been characterized based on their capacity to lower blood glucose levels. The more potent reduction of blood glucose coupled to a more intensive stimulation of insulin...
Book Chapter
Series: Endocrine Development
Volume: 31
Published: 27 January 2016
10.1159/000439372
EISBN: 978-3-318-05639-6
... Abstract This chapter deals with novel therapeutic approaches, predominantly for type 2 diabetes. Incretin-based therapies utilize the effects of glucagon-like peptide-1 (GLP-1), which stimulates insulin and inhibits glucagon secretion in a glucose-dependent manner. Incretin-based therapies...
Book Chapter
Series: Frontiers in Diabetes
Volume: 19
Published: 12 August 2008
10.1159/000152023
EISBN: 978-3-8055-8641-2
... Abstract Recently we have discovered that the incretin hormone glucagon-like peptide-1 (GLP-2) is an important mediator of cell migration and that GLP-2 is also able to increase proliferation of colon cancer cells. We found that dipeptidyl peptidase IV inhibitors - thought to be a treatment...
Book Chapter
Series: Frontiers in Diabetes
Volume: 21
Published: 16 February 2012
EISBN: 978-3-8055-9944-3
...References References 1. Girard J: The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 2008; 34: 550-559 2. Hansotia T Drucker DJ: GIP and GLP-1 as incretin hormones: lessons from...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
EISBN: 978-3-318-05974-8
... of highly active enterogastrone. Can J Physiol Pharmacol 1969;47:113-114. 6. Unger RH, Eisentraut AM: Entero-insular axis. Arch Intern Med 1969;123:261-266. 7. Creutzfeldt W: The incretin concept today. Diabetologia 1979;16:75-85. 8. Bell GI, Santerre RF, Mullenbach GT: Hamster preproglucagon...
Book Chapter
Series: Frontiers in Diabetes
Volume: 28
Published: 03 January 2020
10.1159/000480177
EISBN: 978-3-318-06612-8
.... The pathophysiological traits from pregnancies complicated by GDM, which can be found several years after birth, and how these traits may influence abnormal glucose tolerance later in life are described. GDM shares pathophysiological traits with T2DM and includes increased inflammatory response, altered incretin effect...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475737
EISBN: 978-3-318-05974-8
...-1R) agonists as well as dipeptidyl peptidase-IV (DPP-4) inhibitors are 2 other recommended add-on therapies when metformin alone is incapable of providing suitable glycemic control in T2D patients [ 27 , 28 , 29 ]. GLP-1 is an endogenous peptide that serves as one of the incretin hormones...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 42
Published: 10 April 2014
EISBN: 978-3-318-02639-9
... T, Zhao BR, Bound MJ, Checklin HL, Bellon M, Little TJ, Young RL, Jones KL, Horowitz M, Rayner CK: Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. Am J Clin Nutr 2012;95:78-83. 25. Rorsman P: The pancreatic β-cell...
Book Chapter
Series: Frontiers of Hormone Research
Volume: 43
Published: 12 June 2014
EISBN: 978-3-318-02674-0
.... Salcedo I, Tweedie D, Li Y, Greig NH: Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012;166:1586-1599. 6. Ussher JR, Drucker DJ: Cardiovascular biology of the incretin system...
Book Chapter
Series: Advances in Cardiology
Volume: 45
Published: 14 February 2008
10.1159/000115193
EISBN: 978-3-8055-8428-9
... disease. New possibilities are representedby incretin mimetic compounds, dipeptidyl peptidase (DPP)-4 inhibitors, inhaled insulinand eventually oral insulin. ...
Book Chapter
Series: Endocrine Development
Volume: 31
Published: 27 January 2016
EISBN: 978-3-318-05639-6
...References References 1. Creutzfeldt W: The incretin concept today. Diabetologia 1979;16:75-85. 2. Holst JJ: The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439. 3. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
EISBN: 978-3-318-05974-8
...:reviews3013. 31. Deacon CF: What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005;128:117-124. 32. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53...
Book Chapter
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/000475735
EISBN: 978-3-318-05974-8
.... This observation clearly suggests a weight-independent effect. The observation that patients receiving a gastric banding do not show comparable effects further supports this idea. Subsequent experimental and clinical studies show that incretins (intestinal regulators of the secretion of insulin) might be involved...
Book
Book Cover Image
Series: Endocrine Development
Volume: 32
Published: 21 August 2017
10.1159/isbn.978-3-318-05974-8
EISBN: 978-3-318-05974-8
Book Chapter
Series: Frontiers of Hormone Research
Volume: 42
Published: 10 April 2014
10.1159/000358321
EISBN: 978-3-318-02639-9
... EECs. In addition, studies in rodents failed to find an artificial sweetener-induced release of incretins in vivo. Negative results were also reported in healthy humans: there was no effect of oral sucralose or intragastric sucralose, aspartame, or acesulfame-K on GLP-1, PYY, ghrelin, or GIP secretion...